Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) announced its earnings results on Thursday, March 27th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.13), Zacks reports.
Unicycive Therapeutics Stock Performance
Unicycive Therapeutics stock traded down $0.08 during trading hours on Friday, reaching $0.51. 1,188,656 shares of the company's stock traded hands, compared to its average volume of 1,426,398. The firm has a market capitalization of $52.62 million, a price-to-earnings ratio of -0.52 and a beta of 2.26. Unicycive Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $1.60. The firm's 50 day moving average is $0.58 and its 200-day moving average is $0.57.
Analyst Ratings Changes
Separately, HC Wainwright boosted their price objective on shares of Unicycive Therapeutics from $4.00 to $7.50 and gave the stock a "buy" rating in a research report on Tuesday.
Read Our Latest Report on Unicycive Therapeutics
Unicycive Therapeutics Company Profile
(
Get Free Report)
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Featured Stories
Before you consider Unicycive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.
While Unicycive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
